Androgen and Antiandrogen Protocols: Facial Structure as a Side Effect

Most jawline content fixates on body fat and mewing and stops there. The genuinely interesting lever - and the one almost nobody on the looksmaxxing side talks about cleanly - is the hormonal milieu the face is sitting in. Androgens and antiandrogens don't just shift muscle and libido; they redistribute subcutaneous fat, change skin thickness, alter water retention, and modulate masseter tone. Trans medicine has been running the cleanest natural experiment on this for thirty years, and the before/afters are unambiguous.

The androgen side: what testosterone actually does to a face#

When endogenous or exogenous testosterone rises into the high-physiological or supraphysiological range, several things happen to facial tissue in parallel:

• Subcutaneous fat redistributes away from the cheeks, jowls, and submental area. Androgens promote visceral fat storage and reduce peripheral subcutaneous fat - the face is peripheral. This is the single biggest reason a lean man on TRT looks more angular than the same man hypogonadal at the same body weight.
• Skin thickens and sebum output rises. Dermal collagen density is androgen-responsive. Thicker skin holds shadow lines better and resists the crepey, hollow look that tanks jawline definition in older or under-androgenized faces.
• Masseter hypertrophy. The masseter is androgen-receptor-rich. Heavy chewing plus a high-androgen environment produces visibly wider gonial angles over months. This is why FTM patients on testosterone often report a squarer lower face even without chewing-gum protocols, and why high-dose AAS users sometimes notice their bite feels stronger.
• Water and sodium handling shifts. Aromatizing androgens (testosterone, dianabol, anadrol) push estradiol up, and estradiol drives extracellular water. A face on 500mg test/week with E2 at 60 pg/mL looks puffier than the same face at E2 30 pg/mL. This is the "moonface" community complaint, and it is fully reversible by tightening the aromatase ratio rather than crashing E2.

The practical implication: men running TRT or a blast often credit "fat loss" for facial improvement when the actual driver is a combination of fat redistribution, skin thickening, and masseter recruitment. Crashing E2 with an over-aggressive AI undoes a meaningful fraction of that aesthetic gain - dry, flat, hollow faces are a tell of estrogen mismanagement, not of being lean.

The antiandrogen side: spironolactone, CPA, bicalutamide, and the pill#

The mirror image is well-documented. Antiandrogen exposure - whether from spironolactone for acne or PCOS, cyproterone acetate or bicalutamide in MTF protocols, or oral contraceptives raising SHBG and suppressing free androgens - softens facial structure in predictable ways:

• Cheek and jowl fat returns. Subcutaneous fat redistributes back toward the face, hips, and thighs. MTF patients on estradiol plus an antiandrogen show measurable increases in cheek and lip fat pads within 6-12 months, visible on MRI and obvious in photos.
• Skin thins slightly and oil output collapses. This is why spiro is prescribed for acne in the first place. The aesthetic upside is poreless, smoother skin; the trade-off is a softer, less defined surface over the bone.
• Masseter atrophy. Lower androgen tone reduces masseter cross-sectional area. Combined with fat return to the lower face, the gonial angle visually rounds.
• Reduced facial and body hair density, which softens the jaw shadow line independent of fat.

Cis women on spironolactone for acne or hirsutism frequently notice the cosmetic side effects before the dermatological ones. The r/Spironolactone thread on "does anyone else feel like spiro made you prettier" is full of this exact observation.

"We know that clinically drugs like birth control, estrogen hormone therapy, and anti androgens can change facial structure and quality of skin."

The same mechanism is why combined oral contraceptives - which raise SHBG, lower free testosterone, and add a synthetic progestin with variable androgenic activity - are reported to change facial appearance in either direction depending on the progestin. Drospirenone (a spironolactone analog) and cyproterone-containing pills feminize. Levonorgestrel-based pills are mildly androgenic and do less.

What this means for a looksmaxxing audience#

For men optimizing the jaw, the takeaway is mostly defensive: don't blunt your own androgen signal accidentally.

• Finasteride and dutasteride lower scalp DHT, which is the entire point, but they also lower serum DHT systemically. DHT is a potent driver of dermal thickness and sebum. Some users report subtle facial softening on oral 5-AR inhibitors over years - this is one of the strongest arguments for switching to topical finasteride or routing the AR-blockade work to scalp-only agents like RU58841 or pyrilutamide when on cycle.
• SSRIs, ketoconazole, and high-dose cimetidine all have antiandrogen activity at the receptor or synthesis level. Worth knowing if facial composition is shifting and nothing else changed.
• E2 management on cycle matters more for face than for any other tissue. Run estradiol at the low end of physiological, not crashed. Hollow-cheek look correlates with E2 under 20 pg/mL on TRT.
• Masseter loading (mastic gum, falim gum, isometric clenches) compounds with a high-androgen environment. The same protocol on a hypogonadal man does noticeably less.

For cis women and looksmaxxers running antiandrogens for skin or hair reasons, the trade-off is real and worth being explicit about: spiro will probably improve your skin and soften your jaw simultaneously. Whether that's a win depends on your starting face and your aesthetic target. The cohort that benefits most from spiro cosmetically is people whose acne and seborrhea were dominating the look; the cohort that loses ground is people whose jawline definition was already a strength.

The bone-structure ceiling still applies#

None of this moves the mandible itself in an adult. Hormones move the soft tissue draped over the mandible - fat pads, masseter, skin thickness, water. A weak bony jaw on high-dose testosterone with a trained masseter will look better than the same jaw hypogonadal and unchewed, but it will not look like a structurally strong jaw. The ceiling is bone; the hormonal protocol determines how much of that ceiling you actually express.

Bottom line#

Facial structure is a downstream readout of the androgen-to-estrogen-to-cortisol ratio the tissue has been sitting in for the past several months. Protocols that raise free androgens with controlled estradiol sharpen the face; protocols that suppress androgens or crash estradiol soften or hollow it. Trans medicine has documented this in both directions, and the cis cosmetic literature on spironolactone and oral contraceptives backs it up. Manage E2, keep AR antagonism topical and scalp-local where possible, load the masseter, and the hormonal lever does most of the work the jawline-trainer market is selling gadgets for.